Navigation Links
Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
Date:12/3/2010

SAN MATEO, Calif., Dec. 3, 2010 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that, as anticipated, on November 30, 2010, the Company received a letter from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market (the "Staff Determination") notifying the Company that, based on its failure to regain compliance with the $1.00 minimum bid price requirement, as set forth in NASDAQ Listing Rule 5550(a)(2), the Company's common stock would be subject to delisting from The NASDAQ Capital Market unless the Company requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel").

The Company intends to request a hearing before the Panel, which will stay any action with respect to the Staff Determination until the Panel renders a decision subsequent to the hearing.  There can be no assurance that following the hearing the Panel will grant the Company's request for continued listing on The NASDAQ Capital Market.

The Staff Determination follows a notification from the Staff dated June 1, 2010, which was disclosed by the Company on June 4, 2010, indicating that the minimum bid price of the Company's common stock had been below $1.00 per share for 30 consecutive business days and that the Company had 180 calendar days, or until November 29, 2010, to regain compliance with the minimum bid price requirement.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rat
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Realigns Management
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
4. Nile Therapeutics Reports 2010 Third Quarter Financial Results
5. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. ImmunGenes Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
7. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
8. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
9. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
10. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
11. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... , April 21, 2015  The American ... U.S. Food and Drug Administration that the agency,s ... for the last 25 years to protect the ... homeopathic medicines. AAHP, the industry,s trade association, was ... of homeopathic medicines to engage in productive discussions ...
(Date:4/21/2015)... NEW YORK , April 21, 2015 ... of amendments to its Clinical Trial Authorizations (CTAs) filed ... Regulatory Agency (MHRA) and Germany,s ... (BfArM) for the expansion of the Company,s global Phase ... hepatocellular carcinoma (primary liver cancer, or HCC), to include ...
Breaking Medicine Technology:Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4
... - First prospective biomarker trial in non-small cell ... /PRNewswire-FirstCall/ -- Response,Genetics, Inc. today announced that positive ... issue of the Journal of Clinical,Oncology suggests that ... in patient biopsies,with advanced non-small cell lung cancer ...
... LOS ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. ... Phase,II data on the Company's prostate cancer drug ... Society for,Medical Oncology (ESMO) Conference, which is currently ... in two oral and,poster presentations on Sunday, July ...
Cached Medicine Technology:Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6
(Date:4/21/2015)... 2015 As a provider of holistic, ... that their rehabilitation strategy, which involves various treatment modalities, ... In an effort to offer hope and encouragement to ... lives, Best Drug Rehabilitation has featured a series of ... successful graduates of their recovery program. , One ...
(Date:4/21/2015)... Zane Benefits, the leader in individual ... publication of a new guide “Health Reimbursement Accounts in ... the health insurance industry, including how employers can use ... what is permitted when implementing an HRA. This simple, ... which HRAs are compliant this year. , According ...
(Date:4/21/2015)... April 21, 2015 Zane Benefits, a ... today its CEO Rick Lindquist has been selected as ... , According to Rick Lindquist, “There is a massive ... Zane Benefits’ small business solutions are at its forefront. ... by Employee Benefit Adviser’s Rising Stars.” , According to ...
(Date:4/21/2015)... 21, 2015 Optimity Advisors ( ... advisory firm that helps clients in complex industries ... that the Association of Community Affiliated Plans ... ACAP represents 58 local, not-for-profit, community-affiliated Safety Net ... million people primarily enrolled in public or state-sponsored ...
(Date:4/21/2015)... When a bandage sticks to an injury site ... solve this problem two inventors from Festus, Mo., designed ... helps a cut, burn, abrasion or wound heal more ... The bandage is easy to use, versatile and producible ... to the St. Louis office of InventHelp. It is ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Graduate Discusses Making Amends and Rebuilding Relationships 2Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2
... develop certain hereditary cancers develop them at earlier ages than ... CANCER , a peer-reviewed journal of the American Cancer Society, ... of cancer diagnosis to determine when to provide counseling, screening, ... the BRCA genes have a high risk of developing breast ...
... , SATURDAY, Sept. 10 (HealthDay News) -- It,s important for ... their children to do their homework, a new study suggests. ... toward homework improves if parents take a positive, supportive attitude ... the assignment or getting a higher grade. The study ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, ... Administration advisers recommended Friday that osteoporosis drugs such as ... clarifying how long a patient should take a drug ... drugs, known as bisphosphonates, are taken to prevent fractures ...
... Preliminary research on Fusarium , a group of ... shows how these microbes travel through the air. ... research, there will be a better understanding about crop ... are steering their efforts towards a new aerobiological modeling ...
... A new study finds that lung cancer patients ... percentage of uninsured and Medicaid-insured patients, so-called "high ... undergo surgery that was intended to cure the ... burden facilities. This difference persisted even after controlling ...
... , FRIDAY, Sept. 9 (HealthDay News) -- One-third ... inherited metabolic disorder, a new study finds. This ... produced naturally from many foods -- that has a foul, ... a disease that impairs the ability of an enzyme to ...
Cached Medicine News:Health News:Women who inherit BRCA gene mutations develop cancer earlier than their ancestors 2Health News:Parents' Positive Attitude Can Help Kids Get Homework Done 2Health News:FDA Advisers Call for Revised Labels for Osteoporosis Drugs 2Health News:FDA Advisers Call for Revised Labels for Osteoporosis Drugs 3Health News:Microbes travel through the air; it would be good to know how and where 2Health News:Microbes travel through the air; it would be good to know how and where 3Health News:Study finds hospitals of last resort deliver lower quality of lung cancer care 2
... Nidek GYC-1000 delivers a solid-state ... of energy and plugs into ... compact design and extreme portability, ... with the Nidek Phaco Emulsification ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Medicine Products: